Randomized clinical trial to evaluate the effectiveness of enrofloxacin as a second‐line antibiotic for treatment of acute Escherichia coli mastitis |
| |
Authors: | Kazuhiro Kawai Akira Takeda Michiaki Yamada Fumi Kayasaki Nao Kondo Yoshiko Sasaki Nahoko Kanai Takuma Mukai Naoki Sawaguchi Masaya Higuchi Haruka Kondo Kouki Sugimoto Akane Yasuda Aiko Watanabe |
| |
Institution: | 1. School of Veterinary Medicine, Azabu University, Sagamihara, Kanagawa, JapanEqual contribution;2. Shibecha Veterinary Clinic, NOSAI Doto, Shibecha, Hokkaido, Japan;3. Teshikaga Veterinary Clinic, NOSAI Doto, Teshikaga, Hokkaido, Japan;4. Nijibetsu Veterinary Clinic, NOSAI Doto, Shibecha, Hokkaido, Japan;5. Hamanaka Veterinary Clinic, NOSAI Doto, Hamanaka, Hokkaido, Japan;6. Anebetsu Veterinary Clinic, NOSAI Doto, Hamanaka, Hokkaido, Japan;7. Akkeshi Veterinary Clinic, NOSAI Doto, Akkeshi, Hokkaido, Japan;8. Tsurui Veterinary Clinic, NOSAI Doto, Tsurui, Hokkaido, Japan;9. Akankushiro Veterinary Clinic, NOSAI Doto, Kushiro, Hokkaido, Japan;10. School of Veterinary Medicine, Azabu University, Sagamihara, Kanagawa, Japan |
| |
Abstract: | The objective of the present study was to evaluate the effectiveness of enrofloxacin (ERFX) as a second‐line antibiotic for treatment of acute Escherichia coli (E. coli) mastitis. Forty‐two cows with naturally occurring acute E. coli mastitis were enrolled. On the first day of treatment (day 0), empirically selected antibiotics (oxytetracycline: n = 32, kanamycin: n = 10) were administered. Although systemic signs improved in 10 cows (first‐line group), the signs remained unchanged or worsened in 32 cows on day 1, including two cows that were found dead. The 30 surviving cows were randomly assigned to second‐line groups constituting an ERFX group (n = 19) or a control group (n = 11) that was treated with other antibiotics. Response to each treatment was evaluated by measuring clinical signs from day 0 to day 3, subsequent quarter milk recovery, and the 60‐day survival rate. Appetite on day 3 was significantly better in the ERFX group compared to the control group. No significant differences were observed in the 60‐day survival rate or the subsequent milk recovery between the ERFX group and the control group. Thus, the use of ERFX as a second‐line antibiotic for the treatment of acute E. coli mastitis could induce a rapid appetite recovery. |
| |
Keywords: | enrofloxacin
Escherichia coli
mastitis prospective study second‐line |
|
|